Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important role in disease prognostication. The median age of AML diagnosis is 67 years with nearly […]

Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 7th 2019

We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC.

Questions
1.   Could you tell us a little about the MYSTIC study and its major findings? (00:07)
2.   What was the relationship between programmed death-ligand 1 (PD-L1) expression and the efficacy of durvalumab? (00:50)
3.   How did the expression of PD-L1 differ between primary tumour and metastatic samples? (01:30)
4.    What are the implications of these findings for clinical practice? (01:51)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Neils Reinmuth disclosed a relevant relationship with AstraZeneca.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup